BORDEAUX, FRANCE / SEPTEMBER 18, 2024

The PARKEO2 clinical trial completes its enrollment phase ahead of schedule

PARKEO2 is a groundbreaking study aimed at improving surgical treatments for Parkinson's disease.

RebrAIn, specialized in precise targeting solutions for deep brain stimulation (DBS) treatments and lesion techniques, is proud to announce the early completion of recruitment for the second phase of the PARKEO2 study, funded by the French government and sponsored by the Bordeaux University Hospital (CHU de Bordeaux).

The PARKEO2 trial is based on pioneering research led by Professor Emmanuel Cuny at the Bordeaux University Hospital (CHU de Bordeaux). Professor Cuny's work has been instrumental in laying the foundation for this ambitious study, which aims to expand access to surgery for Parkinson's disease. This research has provided valuable insights into potential therapeutic targets.

PARKEO2 is a randomized study, the first of its kind in the world, conducted a blind comparison of two surgical methods for deep brain stimulation (DBS). This study included 128 patients across 11 renowned sites.

The Assistance Publique - Hôpitaux de Marseille (APHM) distinguished itself as the leading recruitment center, headed by Professor Jean Régis, President of the World Society for Stereotactic and Functional Neurosurgery (WSSFN). At Nice University Hospital (CHU de Nice), Professor Denys Fontaine played a key role in the recruitment and management of the study. Dr. Emile Simon from the "Hospices Civils de Lyon" (HCL), home to the largest functional and stereotactic neurosurgery department in France, completed this trio of excellence.

In addition to his academic achievements, Professor Cuny co-founded RebrAIn, a company that utilizes the targeting technology tested in the PARKEO2 trial. RebrAIn's AI-driven solution replicates the best clinical outcomes post-therapy, streamlining complex, patient-specific neurosurgery by delivering faster, simpler, and safer treatments through augmented neuromodulation planning. RebrAIn's technology, recently approved for its second indication by the FDA, enhances targeting in specific brain areas, enabling more precise and personalized treatments.

About RebrAIn

RebrAIn is a France-based company that provides technology to enable precise targeting for DBS and lesioning treatments for patients suffering from severe Parkinson's or essential tremor disease. Its SaaS solution helps neurosurgeons to precisely identify the target area for surgical intervention. Its novel approach uses machine learning of clinical patient outcomes to predict optimal treatment zone in each patient's brain.

Contact

United States
Robert Law
US Business Development Leader
+1 (734)904-1997
robert.law@rebrain.eu

International
David Caumartin
CEO
david.caumartin@rebrain.eu

The trial is funded by a combination of public (National Clinical Research Hospital Program PHRC-N) and private funds, reflecting broad support and high expectations for its results. The multicenter nature of the study, involving several research centers across different regions, ensures a diverse and comprehensive approach to data collection and analysis. Furthermore, the inclusion of a control group allows for rigorous comparison and validation of the trial's results.

"We are thrilled to have reached this significant milestone ahead of schedule," said Professor Emmanuel Cuny. "The enthusiasm and commitment of our participants and research teams have been truly inspiring. We hope the results of this trial will bring us closer to new, effective treatments for the symptoms of Parkinson's."

Pr. Emmanuel Cuny, Principal Investigator, CHU de Bordeaux, Co-Founder of RebrAIn

PARKEO2 Contacts:
- **David Caumartin,** CEO, david.caumartin@rebrain.eu
- **Emmanuel Cuny,** Principal investigator emmanuel.cuny@chu-bordeaux.f

The PARKEO2 trial is registered on ClinicalTrials.gov under the identifier NCT04884412. For more information about the study and its progress, please visit ClinicalTrials.gov.

For more information about RebrAIn and its services, please visit rebrain.eu.

About RebrAIn

RebrAIn is a France-based company that provides technology to enable precise targeting for DBS and lesioning treatments for patients suffering from severe Parkinson's or essential tremor disease. Its SaaS solution helps neurosurgeons to precisely identify the target area for surgical intervention. Its novel approach uses machine learning of clinical patient outcomes to predict optimal treatment zone in each patient's brain.

Contact

United States
Robert Law
US Business Development Leader
+1 (734)904-1997
robert.law@rebrain.eu

International
David Caumartin
CEO
david.caumartin@rebrain.eu

About the Bordeaux University Hospital (CHU de Bordeaux)
The Bordeaux University Hospital (CHU de Bordeaux) is a leading medical research institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong focus on neurological disorders, CHU de Bordeaux is at the forefront of developing new treatments and improving patient outcomes.

rebrain.eu